Myriad Genetics price to free cash flow MYGN

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 228×; Jul 2021
10-year median: 20.7×
10-year range: 8.1× to 239×
Peer median: 22.8×

Myriad Genetics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2021, at 228×.

On the days it had one over the last ten years, its median was 20.7×, from 8.1× in Jan 2017 to 239× in Jul 2021.

Price to free cash flow over time

median 20.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	228×	197×	239×
2020	21.1×	15.0×	36.7×
2019	24.0×	21.2×	33.2×
2018	28.0×	15.2×	36.3×
2017	18.8×	8.1×	25.4×
2016	8.6×	8.0×	20.4×
2015	20.8×	19.4×	32.9×
2014	31.0×	8.0×	31.0×
2013	9.1×	9.0×	18.6×
2012	14.5×	13.5×	19.1×
2011	13.7×	12.2×	14.5×

Against its peers

Companies in Medical - Diagnostics & Research nearest Myriad Genetics' size, closest first, today.

Company	Price to free cash flow
MYGNMyriad Genetics	n/m
NRCNRC Health	22.4×
ICCCImmucell	22.1×
CDNACareDx	n/m
VCYTVeracyte	23.2×
BLLNBillionToOne	153×
Peer median	22.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Myriad Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.